Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma (Cancer Cell International)

There is a lack of effective treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Furthermore, the response rate of NPC patients to programmed death 1 (PD-1) inhibitors is approximately 20...